AI Engines For more Details: Perplexity Kagi Labs You
Tapeworm Infections: Praziquantel is highly effective against various species of tapeworms (cestodes) that infect humans and animals. It works by causing severe spasms and paralysis of the tapeworm's muscles, leading to detachment of the worm from the intestinal wall and subsequent expulsion from the body through bowel movements. Tapeworm infections that can be treated with praziquantel include Taenia species (such as Taenia saginata and Taenia solium), Dipylidium caninum, and Echinococcus species.
Fluke Infections: Praziquantel is also used to treat infections caused by flukes (trematodes), including liver flukes (such as Fasciola hepatica and Fasciola gigantica), lung flukes (such as Paragonimus westermani), and blood flukes (such as Schistosoma species). Praziquantel disrupts the integrity of the fluke's cell membrane, leading to muscle spasms, paralysis, and eventual death of the parasite.
Schistosomiasis: Schistosomiasis, also known as bilharzia, is a parasitic infection caused by Schistosoma species. Praziquantel is the drug of choice for treating schistosomiasis, as it is highly effective against all species of Schistosoma that infect humans. Treatment with praziquantel helps to eliminate adult worms from the bloodstream and reduce the severity of symptoms associated with schistosomiasis, such as fever, abdominal pain, diarrhea, and hepatosplenomegaly.
Cysticercosis: Praziquantel may be used as part of the treatment regimen for cysticercosis, a parasitic infection caused by the larval stage of the pork tapeworm, Taenia solium. By killing the cysticerci (larvae) in various tissues of the body, praziquantel helps to reduce inflammation and prevent further complications associated with cysticercosis.
Hydatid Disease: Hydatid disease, caused by the larval stage of Echinococcus granulosus, is another condition that can be treated with praziquantel. Praziquantel may be used in combination with surgery to manage hydatid cysts and prevent recurrence of the infection.
Fish Tapeworm Infection: Diphyllobothriasis, an intestinal infection caused by the fish tapeworm Diphyllobothrium latum, can be treated with praziquantel. Praziquantel effectively kills the adult tapeworms residing in the intestines, leading to their expulsion from the body.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | 0.3 | |
| ADHD | 1.1 | 0.3 | 2.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.3 | |
| Allergies | 1 | 0.9 | 0.11 |
| Allergy to milk products | 0.6 | 0.6 | |
| Alzheimer's disease | 1.8 | 1.5 | 0.2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.8 | -1.67 |
| Ankylosing spondylitis | 0.1 | 0.6 | -5 |
| Anorexia Nervosa | 0.3 | 0.8 | -1.67 |
| Antiphospholipid syndrome (APS) | 0.1 | 0.3 | -2 |
| Asthma | 0.8 | 0.5 | 0.6 |
| Atherosclerosis | 0.6 | 0.7 | -0.17 |
| Atrial fibrillation | 0.6 | 0.4 | 0.5 |
| Autism | 1.5 | 1.8 | -0.2 |
| Autoimmune Disease | 0.5 | -0.5 | |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| Biofilm | 0.3 | 0.3 | |
| Bipolar Disorder | 0.6 | 1.1 | -0.83 |
| Brain Trauma | 0.8 | -0.8 | |
| Breast Cancer | 0.6 | 0.3 | 1 |
| Cancer (General) | 0.3 | 0.3 | |
| Carcinoma | 1.2 | 0.3 | 3 |
| Celiac Disease | 0.1 | 0.6 | -5 |
| Cerebral Palsy | 0.8 | -0.8 | |
| Chronic Fatigue Syndrome | 0.8 | 1.4 | -0.75 |
| Chronic Kidney Disease | 1.1 | -1.1 | |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 1.1 | -0.83 |
| Chronic Urticaria (Hives) | 0.1 | -0.1 | |
| Coagulation / Micro clot triggering bacteria | 0.8 | -0.8 | |
| Cognitive Function | 0.8 | 0.5 | 0.6 |
| Colorectal Cancer | 1.6 | 0.8 | 1 |
| Constipation | 0.3 | 1 | -2.33 |
| Coronary artery disease | 0.3 | 0.8 | -1.67 |
| COVID-19 | 0.6 | 1.5 | -1.5 |
| Crohn's Disease | 2 | 1.4 | 0.43 |
| cystic fibrosis | 0.5 | -0.5 | |
| deep vein thrombosis | 1.5 | 0.8 | 0.88 |
| Denture Wearers Oral Shifts | 0.3 | 0.3 | |
| Depression | 1.7 | 1.9 | -0.12 |
| Eczema | 0.3 | 0.3 | |
| Endometriosis | 0.3 | 1.1 | -2.67 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | |
| Epilepsy | 0.3 | 0.3 | |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 0.5 | 1.2 | -1.4 |
| Functional constipation / chronic idiopathic constipation | 0.7 | 1.2 | -0.71 |
| gallstone disease (gsd) | 0.3 | 0.8 | -1.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.6 | |
| Generalized anxiety disorder | 0.6 | 0.8 | -0.33 |
| Gout | 0.9 | 0.6 | 0.5 |
| Graves' disease | 0.3 | 1.1 | -2.67 |
| Gulf War Syndrome | 0.3 | 0.3 | |
| Halitosis | 0.6 | 0.6 | |
| Hashimoto's thyroiditis | 1.1 | 0.3 | 2.67 |
| Heart Failure | 1.1 | 0.8 | 0.38 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.3 | 1.4 | -3.67 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.1 | -0.1 | |
| IgA nephropathy (IgAN) | 0.6 | 0.6 | 0 |
| Inflammatory Bowel Disease | 0.6 | 2 | -2.33 |
| Insomnia | 0.6 | 0.8 | -0.33 |
| Intelligence | 0.3 | 0.1 | 2 |
| Intracranial aneurysms | 0.6 | 0.3 | 1 |
| Irritable Bowel Syndrome | 1.2 | 1.1 | 0.09 |
| ischemic stroke | 0.3 | 0.5 | -0.67 |
| Liver Cirrhosis | 1.7 | 1.7 | 0 |
| Long COVID | 0.9 | 1.9 | -1.11 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.3 | 0.3 | 0 |
| Lymphoma | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0.3 | 0.6 | -1 |
| ME/CFS with IBS | 0.6 | -0.6 | |
| Menopause | 0.5 | -0.5 | |
| Metabolic Syndrome | 1.9 | 1.7 | 0.12 |
| Mood Disorders | 1.7 | 1.7 | 0 |
| Multiple Sclerosis | 1.2 | 1.2 | 0 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 0.5 | -0.5 | |
| Neuropathy (all types) | 0.5 | -0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 1.1 | 0.09 |
| Obesity | 1.8 | 1.8 | 0 |
| obsessive-compulsive disorder | 0.2 | 0.4 | -1 |
| Osteoarthritis | 0.3 | -0.3 | |
| Osteoporosis | 0.8 | 0.8 | |
| pancreatic cancer | 0.6 | 0.6 | |
| Parkinson's Disease | 1.3 | 1.8 | -0.38 |
| Polycystic ovary syndrome | 1.6 | 1.3 | 0.23 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| primary biliary cholangitis | 0.3 | -0.3 | |
| Primary sclerosing cholangitis | 0.3 | 0.6 | -1 |
| Psoriasis | 0.3 | 0.9 | -2 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2 | 1.1 | 0.82 |
| Rosacea | 0.3 | 0.5 | -0.67 |
| Schizophrenia | 1.2 | 1.1 | 0.09 |
| scoliosis | 0.3 | 0.6 | -1 |
| Sjögren syndrome | 0.1 | 0.1 | |
| Sleep Apnea | 0.9 | 1.1 | -0.22 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 0.8 | 0.8 | 0 |
| Systemic Lupus Erythematosus | 0.9 | 0.8 | 0.13 |
| Tic Disorder | 0.3 | 0.1 | 2 |
| Type 1 Diabetes | 0.9 | 0.8 | 0.13 |
| Type 2 Diabetes | 2 | 1.4 | 0.43 |
| Ulcerative colitis | 0.3 | 1.7 | -4.67 |
| Unhealthy Ageing | 1.2 | 0.8 | 0.5 |
| Vitiligo | 0.3 | 0.6 | -1 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
